Valneva’s Q1 Loss Hits €32.1 Million as Management Roadshow and Cost Cuts Aim to Stem 40% Stock Decline
12.06.2026 - 16:05:41 | boerse-global.de
Valneva’s shares have lost more than 40% of their value since the start of 2026, trading at €2.25 — just above a 52-week low of €2.13. To counter the slide, top executives are on an intensive roadshow, presenting the company’s case to institutional investors this week at the Oddo BHF Nextcap Forum. The backdrop is unsparing: first-quarter net loss widened to €32.1 million from €9.2 million a year earlier, while revenue tumbled 37% on weak demand for travel vaccines.
In response, the vaccine developer is undertaking an aggressive cost-cutting drive. The company plans to eliminate 10% to 15% of its global workforce and reduce operating costs by as much as one-third this year. At the end of March, Valneva held €105.3 million in cash; an additional €84 million raised through an April capital increase bolsters the balance sheet. Management is conserving resources to bridge the gap until the next major catalyst arrives.
That catalyst is the Lyme disease vaccine candidate LB6V, co-developed with Pfizer. Phase 3 data released in March showed efficacy above 70%, and the U.S. Food and Drug Administration has granted it fast-track designation. Pfizer is now preparing to submit the marketing application, a step wholly outside Valneva’s control but one that remains the single most important event for the stock. The roadshow also includes the BNP Paribas SMID Cap Conference on June 24, a day before the annual general meeting in Lyon.
Should investors sell immediately? Or is it worth buying Valneva?
Away from the Lyme programme, Valneva has recorded incremental progress. Brazil’s ANVISA in May approved local production of its Chikungunya vaccine, with a domestic institute handling manufacturing. More than 30,000 adults have already received the shot in a pilot campaign. Data for the shigellosis candidate S4V2 are expected by mid-2026; positive Phase 2 results would let Valneva assume full development responsibilities.
The technical picture offers little reassurance. The 200-day moving average sits at €3.70, almost 39% above the current price, while the relative strength index at 38.1 signals persistent selling pressure without reaching oversold territory. Annualised volatility runs near 60%, a factor that gives many institutional buyers pause.
All attention now converges on the June 25 annual general meeting in Lyon, where shareholders will press for a credible route to profitability. Until Pfizer files the Lyme vaccine, Valneva’s fate largely depends on external timelines. Management’s immediate task is to convince investors that the restructuring and pipeline milestones can, over time, reverse the year’s steep decline.
Ad
Valneva Stock: New Analysis - 12 June
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
